IDEAYA Biosciences

News

Servier $210m bet on IDEAYA's uveal melanoma therapy darovasertib seems to have paid off, as a trial sets up regulatory filings later in 2026.

Oncology

Luke Piggot, a principal scientist at Debiopharm, shares some recent data and news about the company's work in DNA damage repair inhibitors.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.